Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Measurable and symptomatic Multicentric Castleman's Disease~* Adequate organ function as assessed by laboratory values evaluated by the investigator to determine eligibility prior to treatment~* Eastern Cooperative Oncology Group performance status of 0, 1, or 2~* Corticosteroids dose that does not exceed 1 mg/kg/day of prednisone, and has remained stable or decreased over the 4 weeks before treatment~Exclusion Criteria:~* Human Immunodeficiency Virus or Human Herpes Virus-8 positive~* Skin lesions as sole measurable manifestation of Multicentric Castleman's Disease~* Previous history of lymphoma~* Malignancies, except for adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or cancer other than lymphoma, from which the patient has been disease-free for 3 or more years~* Concurrent medical condition or disease that may interfere with study participation~* Prior exposure to Interleukin-6 or Interleukin-6 receptor targeted therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Siltuximab+best supportive care (BSC) (Type: EXPERIMENTAL): Siltuximab 11 mg/kg will be administered as a 1-hour intravenous infusion every 3 weeks + BSC.
- Placebo+BSC (Type: PLACEBO_COMPARATOR): Placebo will be administered as a 1-hour intravenous infusion every 3 weeks + BSC. Participants who do not respond to placebo during the blinded treatment period will have option to crossover and receive siltuximab 11 mg/kg which will be administered by 1-hour intravenous infusion every 3 weeks + BSC during the unblinded treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).